A new initiative in the U.K. will fund research into potential treatments for dementia and neurodegeneration.
Neurons in mice spit out monomeric tau when electrically stimulated, hinting that neural activity may help drive the spread of pathological forms of tau in the brain.
In Fragile X syndrome, mRNA from the mutant FMR1 gene binds to its own DNA to suppress protein expression. Could the same thing happen in other repeat expansion diseases?
AstraZeneca’s BACE inhibitor AZD3293 moves forward to a Phase 2/3 trial, joining Merck’s MK-8931 as the most advanced current compounds in this class.
A new grant opportunity will fund projects aimed at understanding the similarities and differences between biomarkers of Alzheimer’s and Parkinson’s diseases.